China Biotech Services Holdings Sustainability Profile
China Biotech Services Holdings Limited, commonly referred to as CBSH, is a prominent player in the biotechnology sector, headquartered in China (CN). Established in 2001, the company has made significant strides in providing comprehensive services across the biopharmaceutical and healthcare industries, focusing on drug development, clinical trials, and regulatory compliance. With a strong operational presence in major regions of China, CBSH offers a unique suite of services that includes laboratory testing, data management, and consulting. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies seeking to navigate the complexities of the biotech landscape. Notable achievements include successful collaborations with leading global firms, underscoring their market position as a key service provider in the rapidly evolving biotech industry.
DitchCarbon Score
How does China Biotech Services Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Biotech Services Holdings's score of 39 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Biotech Services Holdings's reported carbon emissions
In 2024, China Biotech Services Holdings reported total carbon emissions of approximately 394,000 kg CO2e, with Scope 2 emissions accounting for about 339,000 kg CO2e and Scope 3 emissions at approximately 28,800 kg CO2e. The previous year, 2023, saw total emissions of about 843,000 kg CO2e, with Scope 2 emissions at approximately 647,000 kg CO2e and Scope 3 emissions reaching about 63,700 kg CO2e. Notably, in 2022, emissions peaked at approximately 11,273,000 kg CO2e, primarily driven by Scope 2 emissions of about 11,237,000 kg CO2e. Despite these figures, China Biotech Services Holdings has not established specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organization, as it operates independently in this regard. Overall, while the company has made strides in reporting its emissions, it currently lacks formal commitments to reduce its carbon footprint, which is critical in the context of global climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 30,000 | 00,000 | 00,000 | - | - | - |
| Scope 2 | 467,000 | 000,000 | 000,000 | 00,000,000 | 000,000 | 000,000 |
| Scope 3 | 43,700 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
How Carbon Intensive is China Biotech Services Holdings's Industry?
How Carbon Intensive is China Biotech Services Holdings's Location?
China Biotech Services Holdings's Scope 3 Categories Breakdown
China Biotech Services Holdings's Scope 3 emissions, which decreased by 55% last year and decreased by approximately 34% since 2019, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 17% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 75% of Scope 3 emissions.
Top Scope 3 Categories
China Biotech Services Holdings's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
China Biotech Services Holdings has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
